^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Small Cell Lung Cancer
    Drug:Zepzelca (lurbinectedin) (Alkylating agent, Apoptosis stimulant, RNA polymerase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    Pharmamar Press Release
    Title:

    PharmaMar gets the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small-Cell Lung Cancer in Macao, China

    Published date:
    12/04/2023
    Excerpt:
    PharmaMar...announced that its licensing partner, Luye Pharma Group Ltd, has received marketing approval for Zepzelca (lurbinectedin) by the Pharmaceutical Administration Bureau in Macao for the treatment of adult patients with metastatic Small-Cell Lung Cancer (SCLC), with disease progression on or after platinum-based chemotherapy.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    06/15/2020
    Excerpt:
    ZEPZELCA is an alkylating drug indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    04/14/2021
    Excerpt:
    Recommendations: Lurbinectedin [III, C; ESMO-MCBS v1.1 score: 1] is a treatment option for SCLC patients progressing on or after first-line platinum-based ChT [III, C].
    DOI:
    10.1016/j.annonc.2021.03.207
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    SCLC subsequent systemic therapy: Preferred regimens…Lurbinectedin